Therefore, we tested whether CRISPR-Cas9 mediated SIRPA gene knockout in monocytes can enhance ADCP and ADCC against a rituximab-opsonized CD47-expressing cancer cell line, i.e., Raji cells (Figure 7A). This evidence concerns the gene SIRPA and cancer.